{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/b2fb5f0b-0ce7-4e5c-b6e0-9b1febd06aea/6307caf8eb49dd0014391513?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Will therapy with psychadelic drugs become mainstream? ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61409400444fd9068ff27e5f/1650571779254-963a10a79fb954ebe7f32c1eac6cf2ec.jpeg?height=200","description":"<p>Could psilocybin, the active ingredient in magic mushrooms, play a role in the treatment of PTSD, OCD and eating disorders? </p><p><br></p><p>A global series of trials, including one in Tallaght, may add to the evidence that psilocybin can play a unique role in therapy.</p><p><br></p><p>Patrick Freyne talks to Conor Pope about the potential of psychedelic therapy and how decades of research were lost to the \"war on drugs\". </p><p><br></p><p><br></p><p><br></p>","author_name":"The Irish Times"}